
Cape Cod summer hotspot testing its sewage for cocaine to find out how hard islanders have been partying
Officials on the New England island of Nantucket will begin testing the island's sewage for cocaine and other drugs.
Authorities at the Health Department hope the testing will help them understand trends in residents' use of illegal substances, according to the Nantucket Current.
'First, this is baselining - If we can get an idea of the standard usage of drugs, we can see if interventions and behaviors change the rate of consumption,' the town's human services director, Jerico Mele, told the outlet.
'That can give us a scorecard on the efforts and reducing usage. With opiate data, we can confirm our expectations about usage going up around certain times of year, like holidays, or if there are time periods when drug use is heavy.
'We can then communicate to treatment centers to reach out to patients and increase outreach. It's a tool for communicating public safety, to be aware and be expecting.'
Town officials could also use data from the tests to approach outreach and intervention programs led by prevention organizations and medical providers.
Leaders are simultaneously testing sewage for COVID-19 at the Surfside Wastewater Treatment Facility. The funds for that initiative are coming from a state program.
Biobot, a Cambridge-based company specializing in wastewater epidemiology, started examining samples from the island in 2020. The town currently sends two samples weekly.
This month, the company will begin testing sewage for cocaine, fentanyl, methamphetamine, nicotine, and opiates, along with common diseases like influenza and RSV.
'They can use the same samples we take,' said David Gray, the head of the Nantucket Sewer Department. 'The numbers will be interesting. They want to get a baseline, and that's the reason we test for COVID. It's going to be data that is a great forecasting tool.'
Officials said they're not expecting to post the results of the testing publicly.
Still, they will be shared with healthcare partners, said Mele, and shed light on local drug usage.
'Everyone's got a good idea of what the situation is, but we have very little direct measurement,' he said. 'When we get away from our gut to getting data, we get a better picture of what's going on.'
In 2001, a report from the National Drug Intelligence Center identified cocaine, particularly crack cocaine, as the biggest drug threat for Nantucket and surrounding areas.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
42 minutes ago
- Daily Mail
Top medics issue urgent warning over heart drug taken by millions - as makers AstraZeneca are accused of 'misreporting' safety data
Millions of patients at high risk of a fatal heart attack could be taking a drug that may not even be effective, top doctors have warned. Anti-clotting pill ticagrelor was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack. The twice-daily pill, sold as Brilinta, is given to people with acute coronary syndrome —a sudden reduction of blood to the heart—reducing the risk of deadly clots and strokes. Since then, studies have questioned if the AstraZeneca drug is as good as its rivals, such as clopidogrel, with some even suggesting it may even increase the risk of bleeding. Now, experts have discovered 'evidence of serious misreporting' in two clinical trials, pivotal to getting the drug approved in the UK and US, 'raising doubts over its approval'. The BMJ investigation claimed the 'primary endpoint' results—the key measure to determine whether a treatment is effective—for both trials were inaccurately reported in leading cardiology journal Circulation. It also said around a quarter of the readings from machines used in the trials were not included in the data sets, the US medicine's regulator, the Food and Drug Administration (FDA) used to approve the drug. Dr Victor Serebruany, an expert in cardiovascular pharmacology at Johns Hopkins University in Maryland, who has been critical of the drug for over a decade said: 'It's been obvious for years that there is something wrong with the data. Since then, studies have questioned if the AstraZeneca drug is as good as its rivals, such as clopidogrel, with some even suggesting it may even increase the risk of bleeding 'That the FDA 's leadership could look past all these problems—on top of the many problems their own reviewers identified and are now being discovered by The BMJ—is unconscionable. 'We all need to know how and why that happened. 'If doctors had known what happened in these trials, they would never have started using ticagrelor.' In order for ticagrelor to get approved, clinical trials had to prove that it was a better drug than competitors in a phase 3 trial. After phase 3 and drug approval, the FDA and MHRA in the UK, continues monitoring it in phase 4 trials, to see if there are any additional problems with the drug. But the BMJ analysis of two phase 2 trial results found there were instances of patients who's blood 'platelet aggregation dramatically increased'. This is where platelets—a type of blood cell—stick together to form clumps which can lead to blood clots, exactly what the drug aims to prevent. It 'suggests incorrect laboratory readings', the BMJ said. Assessing the readings from platelet machines used at the two trial sites, led by cardiologist Dr Paul Gurbel, they also found more than 60 of the 282 readings were not included in the datasets submitted to the FDA. 'The platelet activity levels not entered were significantly higher than those used in the Circulation papers and FDA datasets,' they claimed. 'It is unclear whose blood was sampled, and why those measurements did not contribute to data in either trial.' A spokesperson for the Sinai Center for Thrombosis Research and Drug Development, which Dr Gurbel leads, said: 'Any allegations of any research misconduct in the two studies are baseless and erroneous.' In the UK, the drug is prescribed around 45,000 times per month on the NHS. According to medicines watchdog the National Institute for Health and Care Excellence (NICE), patients are advised to take the drug twice a day at 90mg for around a year after a heart attack. A lower dose of 60mg, may then be prescribed by doctors for up to a further three years. It may also be taken by those who have suffered a minor stroke or a transient ischaemic attack at 90mg alongside aspirin. The body naturally forms blood clots in order to patch wounds and stop bleeding. But over time, things like age, smoking and excessive weight gain can make blood clots more common. These kinds of clots also become more common after someone has a heart attack or blood vessel disorder, coronary artery disease. When someone overproduces these clots they can clog blood vessels, interrupting blood flow or weakening the walls of blood vessels, causing aneurysms and heart attacks. Circulation and AstraZeneca did not respond to a request for comment from the BMJ. MailOnline has also approached AstraZeneca for comment.


The Independent
2 hours ago
- The Independent
Real Madrid issue health update after Kylian Mbappe hospitalised at Club World Cup
Kylian Mbappe has been discharged from hospital in the United States after a bout of gastroenteritis. The 26-year-old France international missed Wednesday night's 1-1 Club World Cup draw with Al Hilal through illness, with head coach Xabi Alonso revealing he had a fever. Real Madrid subsequently confirmed Mbappe was suffering from 'an acute case of gastroenteritis' and had been admitted to hospital for further tests and treatment. Later on Thursday, the LaLiga club revealed Mbappe had been able to return to the team's training base to continue his recovery. A statement on Madrid's official website said: 'Our player Kylian Mbappe was discharged from the hospital this afternoon and has returned to the Real Madrid training camp. 'Mbappe will continue receiving specific medical treatment and will gradually return to team activity.' Los Blancos are due to play their second Group H fixture against Mexican side CF Pachuca in Charlotte on Sunday. Cincinnati during the early hours of Thursday morning.


The Independent
3 hours ago
- The Independent
Parasitic infection outbreak linked to farm feeding sessions declared over
An outbreak of a parasitic infection linked to public animal feeding sessions at a popular farm in South Wales has been declared over by local health authorities. Cases of cryptosporidium infection began appearing in visitors to the Cowbridge Farm Shop at Marlborough Grange Farm in the Vale of Glamorgan in March, and continued to rise over the next two months. Public Health Wales said on Thursday the outbreak was now officially over after a total of 89 confirmed cases. It was previously confirmed that the infection had led to 16 people requiring hospital care for at least one night. No new cases of the infection have been identified since a multi-agency response meeting held on May 28. The farm stopped all public feeding sessions involving animals, including calves and lambs, on April 29 and continues to co-operate with the investigation. Cryptosporidium is a microscopic parasite that causes gastrointestinal illness and is commonly associated with contact with farm animals. It can spread easily from person to person and poses increased risk to young children and those with weakened immune systems. A full outbreak review will now take place and an outbreak report will be produced looking into the incident. Susan Mably, consultant in health protection at Public Health Wales, said: 'We would like to thank everyone affected by this outbreak for their understanding and co-operation. 'We are particularly grateful to our colleagues from Shared Regulatory Services, Vale of Glamorgan Council, Cardiff and Vale University Health Board and the Animal and Plant Health Agency for their expertise and partnership throughout this investigation.'